|
|
News Breaks | | | | November 12, 2012 | | 08:34 EDT |  | IMMU | Immunomedics' Epratuzumab in Lupus showed long-term efficacy and safety
Immunomedics announced that patients with moderate-to-severe lupus who had received continued cycles of epratuzumab therapy maintained improvements or further improved their lupus disease activity over a timeframe of approximately 4 years. Importantly, lower levels of median corticosteroid use were also maintained throughout the study. Results from this open-label, single-arm extension study of the Phase III ALLEVIATE trials were reported by clinical investigators at the 2012 American College of Rheumatology Annual Scientific Meeting in Washington DC. Immunomedics has licensed the rights to the development and commercialization of epratuzumab to UCB in all autoimmune diseases. | |
|
News For IMMU From The Last 14 Days Check below for free stories on IMMU the last two weeks. |
|
|
| There are no results for IMMU |
|
|
|
|
|
|
